Full-Time

HR Data Specialist

Posted on 6/16/2025

Deadline 6/23/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

No salary listed

Junior

Hyderabad, Telangana, India

Category
Administration
Human Resources
People & HR
Required Skills
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor’s Degree / equivalent qualification in HR and min of 1 year of working with HRIS/HCM systems
  • Strong written and verbal communication skills, strong interpersonal skills
  • Ability to work successfully in a fast paced and continuously changing work environment
  • Detail oriented with a focus on accuracy and quality
  • Advanced proficiency with MS Excel and a proven ability to manipulate data and an ability to learn required business systems
  • Ability to learn quickly and apply knowledge effectively
  • Collaborates effectively in a team environment
Responsibilities
  • Maintain and/or approve all data pertaining to employee records (i.e., transfers, personal information, title changes, etc.) that are entered in Workday through Manager or Employee Direct Access.
  • Complete pending new hire transactions in Workday HCM after the candidate is in Ready to Hire status in the ATS
  • Support execution of employee movement, employee status, time off and leave absence, payroll, benefits/leaves, Performance Check-ins, and compensation processes, by maintaining the accurate and on time data in Workday, relevant for the above processes
  • Support the integrity of employee records and Workday data, assuring legal and regulatory compliance.
  • Maintain supervisory organizations, organization assignments, and position titles in the Workday system
  • Complete weekly payroll reconciliation reviewing audit reports, analyzing discrepancies, and processing appropriate updates.
  • Support new hire benefits enrollment including ensure all required documents are collected; Accurately enter benefit enrollment data into systems; Ensure that all benefit enrollment processes adhere to company policies, following the process: Address any issues or discrepancies related to benefit enrollment promptly and effectively.
  • Support the global recognition program
  • Support leave of absence transactions
  • Process Employee Reimbursement Transactions including validate documentation submitted by employee and request reimbursement for employees via payroll.
  • Participate in the review of integration kickout reports from various systems and process updates in Workday based on the identified discrepancies
  • Participate on ad-hoc projects and perform other duties as assigned.
  • Directly participate to enhance and improve the content/FAQ/LWI based on the feedback received via case resolution, by collaborating with functional teams to achieve this
  • Identify and troubleshoot issues and escalate as appropriate
  • Make process recommendations to achieve operational excellence
  • Participate in scheduled and ad hoc training or other forms of learning opportunities in order to improve process acumen, and apply the learnings in executing their role, and to develop their own skills as per needed
  • Work collaboratively within the HR team to share ideas, ownership, and accountability for driving improvements and consistency of execution for key HR processes, across regions and functional areas
  • Identify and report cases trends or product trends to the management team and Senior WFA and work collaboratively with them or other HR functional teams to improve the HR service we provide to our workforce.
  • Collaborate with all functional teams in order for People Service to collectively achieve TAT and FLR
Desired Qualifications
  • Knowledge of Workday
  • Experience working within an HR Shared Services delivery model
  • Have worked in a multi-cultural/multi-country work environment

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high quality and safety standards. Unlike many competitors, BMS emphasizes sustainability and corporate responsibility, focusing on Environmental, Social, and Governance (ESG) goals. Their goal is to improve patient outcomes by providing both innovative and affordable healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with BioNTech enhances BMS's oncology portfolio against competitors like Merck.
  • Chris Shibutani's appointment may drive strategic growth and innovation at BMS.
  • $40 billion US investment shows BMS's commitment to long-term growth and innovation.

What critics are saying

  • Heavy reliance on real-world data may affect drug approval if data quality falters.
  • $11.1 billion BioNTech partnership could strain finances if results are underwhelming.
  • Recent layoffs may impact operational efficiency and employee morale at BMS.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company integrates real-world data to enhance drug development and patient outcomes.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

PharmaData
Jun 13th, 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

Bristol Myers Squibb highlights targeted protein degradation advances, including CELMoD agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy.

Hit Consultant
Jun 10th, 2025
From Raw Records To Real-Time Insights: Climbing Pharma’S Real-World Data Maturity Curve

Viraj Narayanan, CEO at Cornerstone AI Daniel Lane, Head of RWD Strategy & Operations at Bristol Myers SquibbReal-world data (RWD) has become the pharmaceutical industry’s most promising yet challenging frontier. While companies have long recognized its potential to complement clinical trials and deepen patient outcome insights, many still struggle to fully realize its value.We’ve seen firsthand, from early discovery to market authorization to post-launch evidence generation, that extracting meaningful value from RWD requires more than just data acquisition. It demands a consistent, scalable, and repeatable approach to data quality, as well as a strategic roadmap that moves an organization from minimal use of RWD to a position of true leadership. This journey isn’t simple, but for those committed to navigating it, the competitive advantages are substantial. And, importantly, RWD holds the potential to help bring lifesaving and life-changing medications to market faster and safer than ever before.From Data Collection to MaturityPharma’s growing reliance on RWD has encouraged an influx of partnerships with data aggregators, medical institutions, and digital health platforms. Yet, not all companies are at the same level of maturity in using that data effectively

Devdiscourse
Jun 2nd, 2025
Reuters Health News Summary

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda.

The Motley Fool
Jun 2nd, 2025
Why BioNTech Stock Soared Today

BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327.